Developing Novel Tests to Screen for Fetal Growth Restriction.

Fetal growth restriction (FGR) is a major determinant of global morbidity and mortality. There is an unmet need for methods to stratify the pregnant population on the basis of FGR risk. Despite evolutionary divergence in mammalian reproduction, studies of genetically modified mice have identified biomarkers that have been validated in women, and a systematic screen for genes that control fetal growth in animals could help identify novel clinical biomarkers. Current approaches to biomarker identification using human samples include both targeted and discovery approaches (omics). Application of omic methods to the placenta and maternal blood has yielded promising results, but comes with logistical, experimental, and analytical challenges and all studies are limited by the lack of a gold standard for disease.